维拉斯特姆肿瘤
VSTM
8.65
-0.58
-6.28%
维拉斯特姆肿瘤
US · VSTM
#3468 按市值排名
8.65
-0.58
-6.28%
实时 - 追踪5344个代码 - 心跳于296秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例下降了0.6个百分点。
机构持股
- 机构持股比例
- 110.03% -0.56pp
- 机构数量
- 182 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund47.18%
Mutual Fund42.11%
VC/PE Fund11.82%
Public Company6.08%
Private Company1.35%
Family Office/Trust1.21%
Individual/Insider0.73%
Insurance Company0.26%
主要股东 截至 2026-06-30
BlackRock
10.15% · 9.19M 股
Armistice Capital LLC
7.76% · 7.02M 股
RTW Investments, LP
7.33% · 6.64M 股
Deep Track Capital, LP
6.34% · 5.74M 股
State Street Global Advisors
5.67% · 5.13M 股
Vanguard Capital Management, LLC
4.93% · 4.47M 股
Rosalind Advisors, Inc.
4.40% · 3.99M 股
Polar Capital Holdings Plc
4.09% · 3.70M 股
Nantahala Capital Management, LLC
3.96% · 3.58M 股
Stonepine Capital Management LLC
3.70% · 3.35M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 12次买入 · 38次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Daniel Paterson | Chief Executive Officer | 0.34% |
| Brian Stuglik | Director | 0.15% |
| Daniel Calkins | Head of Investor Relations, VP of Finance and Principal Accounting Officer & Financial Officer | 0.08% |
| Robert Gagnon | Director | 0.04% |
| Michelle Robertson | Independent Director | 0.02% |
| Anil Kapur | Independent Director | 0.02% |
| Eric Rowinsky | Independent Director | 0.02% |
| John Johnson | Independent Director | 0.02% |
| Karin Tollefson | Director | 0.02% |
| Michael Kauffman | Lead Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Daniel Paterson | Chief Executive Officer | Open Market Disposition | -44,121 | $8.00 |
| 2026-09-30 | Daniel Calkins | Head of Investor Relations, VP of Finance and Principal Accounting Officer & Financial Officer | Open Market Disposition | -2,566 | $8.00 |
| 2026-09-29 | Daniel Paterson | Chief Executive Officer | Other Acquisition | +106,893 | -- |
| 2026-09-29 | Daniel Calkins | Head of Investor Relations, VP of Finance and Principal Accounting Officer & Financial Officer | Other Disposition | -8,333 | -- |
| 2026-09-20 | Daniel Calkins | Head of Investor Relations, VP of Finance and Principal Accounting Officer & Financial Officer | Open Market Disposition | -55 | $7.70 |
| 2026-08-02 | Daniel Paterson | Chief Executive Officer | Open Market Disposition | -1,302 | $5.81 |
| 2026-07-22 | Robert Gagnon | Director | Intent to Sell (Form 144) | -31,924 | $5.89 |
| 2026-06-24 | Robert Gagnon | Director | Intent to Sell (Form 144) | -21,492 | $4.21 |
| 2026-06-21 | Daniel Paterson | Chief Executive Officer | Open Market Disposition | -20,871 | $4.18 |
| 2026-06-21 | Daniel Calkins | Head of Investor Relations, VP of Finance and Principal Accounting Officer & Financial Officer | Open Market Disposition | -4,089 | $4.13–4.18 |
| 2026-05-26 | Robert Gagnon | Director | Intent to Sell (Form 144) | -20,103 | $4.36 |
| 2026-05-20 | Michael Bailey | Director | Other Acquisition | +108,000 | -- |
| 2026-05-20 | Paul A. Bunn | Independent Director | Other Acquisition | +36,000 | -- |
| 2026-05-20 | Eric Rowinsky | Independent Director | Other Acquisition | +36,000 | -- |
| 2026-05-20 | John Johnson | Independent Director | Other Acquisition | +36,000 | -- |
| 2026-05-20 | Brian Stuglik | Director | Other Acquisition | +36,000 | -- |
| 2026-05-20 | Anil Kapur | Independent Director | Other Acquisition | +36,000 | -- |
| 2026-05-20 | Michelle Robertson | Independent Director | Other Acquisition | +36,000 | -- |
| 2026-05-20 | Karin Tollefson | Director | Other Acquisition | +36,000 | -- |
| 2026-05-03 | Daniel Paterson | Chief Executive Officer | Open Market Disposition | -806 | $5.82 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:22 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
维拉斯特姆肿瘤 讨论区 0 条评论